References
- Guise TA, Mundy GR. Cancer and bone. Endocrine Rev 1998; 19: 18–54.
- Witte RS, Koeller J, Davis TE, et al. Clodronate-a rando-mized study in the treatment of cancer-related hypercalcemia. Arch Intern Med 1987; 147: 937–9.
- Guise TA, Yin JJ, Taylor SD, et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996; 98: 1544–9.
- Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, Hiraga T. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer 2000; 88: 2979–88.
- Grill V, Rankin W, Martin TJ. Parathyroid hormone-related protein (PTHrP) and hypercalcemia. Eur J Cancer 1998; 34: 222–9.
- Hughes DE, MacDonald BR, Russell RGG, Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 1989; 83: 1930–5.
- Selander KS, Mönkkönen J, Karhukorpi E-K, Härkönen P, Hannuniemi R, Väänänen HK. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol 1996; 50: 1127–38.
- Coxon FP, Helfrich MH, van't Hof RJ, et al. Protein geranylgeranylation is required for osteoclast formation, func-tion, and survival: Inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 2000; 15: 1467–76.
- Rotstein S, Glas U, Eriksson M, et al. Intravenous clodronate for the treatment of hypercalcaemia in breast cancer patients with bone metastases-a prospective randomised placebo-controlled multicentre study. Eur J Cancer 1992; 28A: 890–3.
- Gucalp R, Theriault R, Gill I, et al. Treatment of cancer-associated hypercalcemia. Arch Intern Med 1994; 154: 1935–44.
- O'Rourke NP, McCloskey EV, Vasikaran S, Eyres K, Fern D, Kanis JA. Effective treatment of malignant hypercalcemia with a single intravenous infusion of clodronate. Br J Cancer 1993; 67: 560–3.
- Die IJ, Mundy GR. Bisphosphonates in the adjuvant treat-ment of cancer: experimental evidence and first clinical results. Br J Cancer 2000; 82: 1381–6.
- O'Rourke NP, McCloskey EV, Kanis JA. Tumour induced hypercalcaemia: A case for active treatment. Clin Oncol 1994; 6: 172–6.
- Nussbaum SR, Younger J, VandePol CJ, et al. Single-dose intravenous with pamidronate for the treatment of hypercalce-mia of malignancy: Comparison of 30-, 60-, and 90-mg dosages. Am J Med 1993; 95: 297–304.
- Purohit OP, Radstone CR, Anthony C, Kanis JA, Coleman RE. A randomized double-blind comparison of intravenous pamidronate and clodronate in the hypercalcemia of malig-nancy. Br J Cancer 1995; 72: 1289–93.
- Major PP, Lipton A, Berenson J, Hortobagyi G. Oral bispho-sphonates. Cancer 2000; 88: 5–14.